Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 3/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19946521 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Bromide SCHEMBL986162 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL196879 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL987207 | 0.95 | CYP3A4 (0.41) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL29179 | 0.95 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL689027 | 0.92 | TDP1 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL2920316 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL28797563 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9322645 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL30486913 | 0.92 | CYP3A4 (0.43) | CYP3A4TDP1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-19 | — | — | US | claimed |
| US-20230144449-A1 | TERMINAL FUNCTIONAL SIDE CHAIN-SUBSTITUTED DIKETOPYRROLOPYRROLE (DPP)-BASED TERPOLYMER AND PREPARATION METHOD AND USE THEREOF | BEIJING INSTITUTE OF GRAPHIC COMMUNICATION (CN) | 2023-05-11 | — | — | US | claimed |
| EP-4159728-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-05 | — | — | EP | claimed |
| WO-2021259203-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | 正大天晴药业集团股份有限公司 | 2021-12-30 | — | — | WO | claimed |
| WO-2021129082-A1 | METHOD FOR SYNTHESIZING α-ACRYLIC ACID COMPOUND BY USING PALLADIUM TO CATALYZE CARBON DIOXIDE AND ALKYNE | 华南理工大学 | 2021-07-01 | — | — | WO | claimed |
| EP-2272831-A1 | Process for the preparation of arylpyridinyl compounds | Prime European Therapeuticals S.p.A. (IT) | 2011-01-12 | — | — | EP | claimed |
| US-20090124577-A1 | Intermediate Compounds for the Preparation of an Angiotensin II Receptor Antagonist | ENANTIA SI | 2009-05-14 | — | — | US | claimed |
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | claimed |
| EP-0914318-A1 | PYRAZINES | KINGS COLLEGE LONDON (GB) | 1999-05-12 | — | — | EP | claimed |
| WO-1997043267-A1 | PYRAZINES | KINGS COLLEGE LONDON (GB) | 1997-11-20 | — | — | WO | claimed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | claimed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4087836-B1 | PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS | CANTERO THERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-4831144-A | 1H-pyrrolo [3,2-c]pyrrolidines protected in 1-position useful as intermediates | SANOFI (FR) | 1989-05-16 | — | — | US | disclosed |
| EP-0070185-B1 | PREPARATION OF LOWER ALKYL 2-FORMYL-3-(6-METHYL-3-PYRIDINYL)-PROPIONATES | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-10 | — | — | EP | disclosed |
| EP-0070185-A1 | Preparation of lower alkyl 2-formyl-3-(6-methyl-3-pyridinyl)-propionates | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124577-A1 | Intermediate Compounds for the Preparation of an Angiotensin II Receptor Antagonist | AGTR2, AGTR1, ACE | CYP3A4 230/4885TDP1 4557/4885KDM4E 3293/4885 |
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CDK4, CDK6, CDK2 | CYP3A4 968/4885TDP1 1083/4885KDM4E 381/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CYP3A4 1957/4885TDP1 1883/4885KDM4E 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.